Our Top 5 Analyst Questions

Solventum’s first quarter results reflected the impact of ongoing transformation initiatives, new product launches, and portfolio adjustments. Management pointed to strong commercial execution and positive volume and mix as contributing factors. CEO Bryan Hanson credited “the team’s ability to drive outcomes while navigating ongoing separation efforts, ERP implementations, and acquisitions and divestitures” as key to the quarter’s performance. Hanson also highlighted that advanced wound care, dental, and health information systems saw momentum, with particular strength in autonomous coding solutions and the integration of Acera in the wound care business.

Is now the time to buy SOLV? Find out in our full research report (it’s free).

Solventum (SOLV) Q1 CY2026 Highlights:

• Revenue: $2.01 billion vs analyst estimates of $1.97 billion (3% year-on-year decline, 1.9% beat)

• Adjusted EPS: $1.48 vs analyst estimates of $1.35 (9.3% beat)

• Adjusted EBITDA: $468.8 million vs analyst estimates of $426.1 million (23.4% margin, 10% beat)

• Management reiterated its full-year Adjusted EPS guidance of $6.50 at the midpoint

• Operating Margin: 4%, down from 7.3% in the same quarter last year

• Organic Revenue rose 2.1% year on year (miss)

• Market Capitalization: $12.84 billion

While we enjoy listening to the management’s commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Solventum’s Q1 Earnings Call

• Brett Adam Fishbin (KeyBanc Capital Markets) asked about the impact of ERP-related advanced ordering on segment performance; CFO Wayde McMillan explained this would mostly affect infection prevention, surgical solutions, and dental, with full normalization expected later in the year.

• David Roman (Goldman Sachs) questioned the relative contributions of volume and mix to revenue growth; CEO Bryan Hanson said most growth was volume-driven, with price staying in the plus/minus 1% range, and new products making a growing impact.

• Ryan Zimmerman (BTIG) queried the experience gained from ERP cutovers in Asia and how it informs U.S. plans; McMillan said prior cutovers provided valuable lessons, and most volume shifting in Q1 was due to separation activities rather than ERP.

• Jason M. Bednar (Piper Sandler) asked whether the U.S. ERP migration would result in immediate OpEx savings; McMillan clarified that while immediate cost benefits are limited, the Transform for the Future program is designed to capture longer-term efficiencies as new systems are implemented.

• Rick White (Stifel) pressed for more detail on the sales phasing effect in Q2 and how it would be modeled; McMillan advised keeping Q2 models unchanged and pledged to provide sales phasing disclosure in future updates.